SpringWorks Therapeutics Inc. has completed its merger transaction, as outlined in a recent Form 8-K filing. As a result of the merger, each share of SpringWorks' common stock was automatically converted into the right to receive $47.00 in cash, minus applicable taxes. Additionally, vested stock options were canceled, entitling holders to cash payments based on the difference between the merger consideration and the exercise price. Restricted stock unit awards, whether vested or not, have been converted into cash-based awards, with a portion of unvested awards set to vest nine months post-transaction, contingent on continued employment.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.